CAS: 110267-81-7; (7S,9S)-9-Acetyl-9-Amino-7-(((2S,4S,5R)-4,5-Dihydroxytetrahydro-2H-Pyran-2-yl)Oxy)-6,11-Dihydroxy-7,8,9,10-Tetrahydrotetracene-5,12-Dione
该化合物是一种合成的炭疽衍生物,主要用作癌症治疗中的抗乳胶剂,其特点是能够将血浆分解成DNA,从而抑制二类异构酶,从而干扰DNA复制和转录,最终导致细胞死亡.氨绿素展示了各种类型的癌症,特别是治疗肺癌和其他固态肿瘤的多种活动.其化学结构包括一种四环环系统,这是炭疽杆菌的典型特征,它拥有一种有助于其药理特性的氢氧基化合物.该化合物通过静脉注射进行,并因其潜在副作用而闻名,包括乳房压抑,心身毒性和胃肠扰动.由于它的能性,在治疗期间,对病人的仔细监测至关重要.氨绿素的功效和安全特征使其在肿瘤药理学景观中成为有价值的选择,特别是对于未对其他治疗作出反应的病人而言.
- 英文名称(7S,9S)-9-Acetyl-9-Amino-7-(((2S,4S,5R)-4,5-Dihydroxytetrahydro-2H-Pyran-2-yl)Oxy)-6,11-Dihydroxy-7,8,9,10-Tetrahydrotetracene-5,12-Dione
- 中文名称氨柔比星
- IUPAC名称(7S,9S)-9-acetyl-9-amino-7-(((2S,4S,5R)-4,5-dihydroxytetrahydro-2H-pyran-2-yl)oxy)-6,11-dihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione
- 其它别名(7S,9S)-9-Acetyl-9-amino-7-[(2-deoxy--D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione; (7S)-9β-Amino-9-acetyl-7β-[(2-deoxy-β-D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxynaphthacene-5,12-dione; (7S,9S)-9-Acetyl-9-amino-7-(2-deoxy-β-D-erythro-pentopyranosyloxy)-6,11-dihydroxy-5,7,8,9,10,12-hexahydro-5,12-naphthacenedione; (7S,9S)-9-Amino-9-acetyl-7-[(2-deoxy-β-D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxynaphthacene-5,12-dione; Amurubicin
- CAS编号110267-81-7
- MFCD编号:MFCD00868680
- FDA UNII编号:93N13LB4Z2
- 分子式:C25H25NO9分子量:483.47
- 产品CID: 140442
- 同类组份化合物CAS92395-36-3 (HCl)110267-81-7 (free base)110311-30-3
- 产品分类医药中间体 → 原料药中间体
物理性质
MSDS等安全信息
上下游产品
(+)-9-Amino-4-Demethoxy-9-Deoxy-7-O-(2-Deoxy-3,4-Di-O-Acetyl-β-D-Erythro-Pentopyranosyl)Daunomycinone 110267-80-6Amrubicinone 92395-41-0
2-Acetamido-5,8-Dimethoxy-1,2,3,4-Tetrahydro-2-Naphthoic Acid 110191-56-5
合成工艺路线路线简述
📜氨柔比星中间体2置于吡啶,Sodium Hydroxide,三氯化铝,1,3-二溴-5,5-二甲基海因,硫酸,Silver Trifluoromethanesulfonate,Sodium Hydride,Potassium Carbonate,对甲苯磺酸,1,1,3,3-四甲基脲,Sodium Chloride,锌体系中,用 甲醇,乙醚,二氯甲烷,甲苯,苯 用作溶剂,化学反应 58.82H,反应生成氨柔比星
参考文献:Stereospecific Total Synthesis Of 9-Aminoanthracyclines: (+)-9-Amino-9-Deoxydaunomycin And Related Compounds
标题:Stereospecific Total Synthesis Of 9-Aminoanthracyclines: (+)-9-Amino-9-Deoxydaunomycin And Related Compounds
摘要:
Doi:10.1021/jo00229A010
海关参考信息
- 2902600000-乙苯
2905122000-异丙醇
2905310000-1,2-乙二醇
2905320000-1,2-丙二醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:WO-2010125466-A1
优先权日:2009-04-28
标题 :Methods for the synthesis of amrubicin
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Liu CQ, Tian D, Wang N, Meng XP, Yang JD, Li HW, Zhao N, Zhao S, Liao F, Cui Y. Efficacy and safety of amrubicin-based regimen used as first-line for extensive-disease small-cell lung cancer: A meta-analysis of randomized controlled trials. Asia Pac J Clin Oncol. 2018 Apr;14(2):e81-e87. doi: 10.1111/ajco.12778. Epub 2017 Oct 25. A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients. Cancer Chemother Pharmacol. 2017 Sep;80(3):615-622. doi: 10.1007/s00280-017-3403-9. Epub 2017 Jul 31.
3: von Pawel J, Jotte R, Spigel DR, O'Brien ME, Socinski MA, Mezger J, Steins M, Bosquée L, Bubis J, Nackaerts K, Trigo JM, Clingan P, Schütte W, Lorigan P, Reck M, Domine M, Shepherd FA, Li S, Renschler MF. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014 Dec 10;32(35):4012-9. doi: 10.1200/JCO.2013.54.5392. Epub 2014 Nov 10.
合成参考文献
摘要:http://www.lookchem.com/Amrubicin/
📝 需求与反馈
尽可能描述清楚需求与问题信息
